Humira deal with Amgen is a clear vindication of AbbVie’s patent strategy

AbbVie recently settled its dispute with Amgen, whose Amjevita biosimilar it accused of infringing its patents for Humira, the world’s best-selling drug. Though clearing an eventual path to market for Amgen’s drug, the deal constitutes a major…

Unlock unlimited access to all IAM content